A sourced review of peer-reviewed data on how antidepressant medications perform over time, alongside an FDA-approved rapid-acting option and investigational treatments now under study for patients who do not respond to standard care.

SOUTH HAMPTON, NH / ACCESS Newswire / July 16, 2026 / Psychedelic Connect has published a review of peer-reviewed research examining how well antidepressant medications perform over time and what the published evidence shows for the large share of patients who do not achieve lasting relief. The review draws on published studies and government data and presents findings alongside their documented counterpoints.

Federal legal status: The psychedelic compounds referenced in this review are Schedule I controlled substances under U.S. federal law and are not legally available outside FDA-approved clinical trials in most states.

Roughly 11.4% of U.S. adults-nearly one in eight-reported taking prescription medication for depression, according to 2023 data from the U.S. Centers for Disease Control and Prevention. The review examines two questions about that care: how durable the benefit is, and how complete the underlying evidence base is.

Durability of benefit. The original STAR*D trial, the largest study of antidepressant treatment ever conducted, reported a cumulative remission rate of roughly 67% across up to four sequential treatment steps, according to findings published by Rush and colleagues in the American Journal of Psychiatry in 2006. A later reanalysis of the trial's patient-level data, published by Pigott and colleagues in BMJ Open in 2023, found that after accounting for relapse and dropout across twelve months, only about 3% of the more than 4,000 enrolled patients reached remission and stayed there. The two figures measure different things-ever reaching remission versus remaining well a year later-and the distance between them is central to the review.

Completeness of the evidence. An analysis of the full set of antidepressant trials registered with the U.S. Food and Drug Administration (FDA), published by Turner and colleagues in the New England Journal of Medicine in 2008, found that 94% appeared positive in published journals while only 51% were positive in the FDA's complete record; nearly a third of the trials were never published. A separate meta-analysis of the complete FDA dataset, led by Irving Kirsch and published in PLoS Medicine in 2008, found an average improvement of 1.8 points on the Hamilton depression scale over placebo-below the threshold the United Kingdom's guideline body considers clinically meaningful except in the most severely depressed patients. For balance, the largest analysis conducted to date, led by Andrea Cipriani and published in The Lancet in 2018 and covering 522 trials and more than 116,000 participants, found that all 21 antidepressants studied outperformed placebo, though the effects were modest.

An FDA-approved rapid-acting option. For patients who do not respond to standard antidepressants, the FDA approved esketamine nasal spray, sold as Spravato, in January 2025 as the first monotherapy for treatment-resistant depression-defined as an inadequate response to at least two oral antidepressants. The pivotal monotherapy trial, published by Janik and colleagues in JAMA Psychiatry in 2025, found significantly higher remission rates at four weeks than placebo among its 378 participants.

Emerging research beyond standard care. Beyond medication, controlled research into psychedelic-assisted therapy for depression and post-traumatic stress disorder has earned Breakthrough Therapy designations from the FDA. In one Phase 3 trial published by Mitchell and colleagues in Nature Medicine in 2021, 67% of participants with severe PTSD no longer met diagnostic criteria after psychedelic-assisted therapy, compared with 32% who received placebo plus therapy-a preliminary result from a single early-stage study of 90 participants involving investigational treatments that are not approved by the FDA for this use and remain Schedule I under federal law. Separate controlled research published in JAMA Psychiatry in 2021 has reported improvements in treatment-resistant depression, though those trials are small and preliminary. These therapies have also historically drawn less research funding for a structural reason: naturally occurring compounds, including those found in certain fungi and plants, cannot be patented the way novel pharmaceuticals can, which leaves less commercial incentive to fund the large, costly trials needed to establish efficacy. This research remains early-stage, and results from small trials do not predict outcomes in general practice.

Conclusion. The review finds that a large group of patients remains underserved by current standard care, and that both an FDA-approved rapid-acting treatment and a growing body of investigational research now exist for that group. It does not recommend any specific treatment. Decisions to start, stop, or change any therapy should be made with a qualified physician.

The full analysis, with charts and a complete source list, is available at https://psychedelic-connect.com/the-antidepressant-gap/

Media contact:
Psychedelic Connect
contact@psychedelic-connect.com
(866) 435-7057

This release is for informational and educational purposes and is not medical advice. Treatments discussed carry medical and, in some cases, legal risks and are not appropriate for everyone; investigational treatments are not FDA-approved for the uses described. Anyone considering changes to treatment should consult a qualified physician. If you are in crisis, call or text 988 (Suicide & Crisis Lifeline), available 24/7.

SOURCE: Psychedelic Connect LLC